Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT05020652
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College, Tianjin, Tianjin, China
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT05021367
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Cen, Guangzhou, Guangdong, China
A Study of TQB3820 in Patients With Hematological Malignancies
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT05020639
- Locations
- 🇨🇳
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China
🇨🇳Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing, China
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05011019
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, Shanghai, China
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT04975204
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, Tianjin, China
🇨🇳Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 375
- Registration Number
- NCT04964479
- Locations
- 🇨🇳
Three Gorges Hospital of Chongqing University, Chongqing, China
🇨🇳Southern Hospital of Southern Medical University, Guangzhou, China
🇨🇳Zhujiang Hospital of Southern Medical University, Guangzhou, China
A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 344
- Registration Number
- NCT04955834
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04956328
- Locations
- 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT04944043
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei, Anhui, China
🇨🇳Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)
- Conditions
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT04941404
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Hematology Hospital of the chinese Academy of Medical Sciences, Tianjing, Tianjing, China